HOME >> BIOLOGY >> NEWS
Carnegie Mellon U biologists identify critical player in yeast ribosome assembly

PITTSBURGH--Carnegie Mellon University biologists are the first to show that minor changes in the tail of one protein cripple yeast's ability to assemble protein-making machines called ribosomes. The findings, published in a recent issue of Molecular Cell, ultimately could help scientists develop better drugs to fight fungal infections.

"Our findings are the first to link the structure of a ribosomal protein to a critical step in the pathway to assembling a fully functional ribosome," explained John Woolford, professor of biological sciences at the Mellon College of Science at Carnegie Mellon. "Understanding the molecular basis of ribosome assembly offers a rational scheme for designing drugs to interfere with that process."

A complex of protein and ribonucleic acid (RNA), ribosomes are present in vast quantities inside every cell. There, they translate genetic information into proteins that control many activities, including cell movement, metabolism, division and response to the environment. Because ribosomes are essential for protein production, problems with their assembly inevitably spell cell death.

Woolford found that changing the tail of a ribosomal protein called S14 prevented it from processing a chunk of RNA destined to become part of a mature ribosome. Drugs that target the tail of S14 would likely interfere with ribosome assembly, according to Woolford, who added that such agents would destroy an infectious fungus while leaving animal or plant cells unharmed.

Using processes known as transformation and gene disruption, Woolford's group engineered the yeast Saccharomyces cerevisiae, (common baker's yeast) to contain two genes for S14. One normal, or wild-type, gene instructed production of a fully functional S14 protein, while a mutant gene coded for the production of an S14 with an altered tail. After growing the yeast under normal conditions, Woolford turned off the wild-type gene and observed the consequences when only t
'"/>

Contact: Lauren Ward
wardle@andrew.cmu.edu
412-268-7761
Carnegie Mellon University
7-Jun-2004


Page: 1 2

Related biology news :

1. Carnegie Mellon researcher tests tools for protecting Anacostia River ecosystem from PCBs
2. Carnegie Mellon scientists reveal ways of studying, resolving PCB contamination in US rivers
3. PCB breakdown in rivers depends on sediment-specific bacteria, find Carnegie Mellon U. scientists
4. Carnegie Mellon researchers to demonstrate autonomous robotthat will seek life in Atacama Desert
5. Carnegie Mellon University hosts ACS-PRF summer school on green chemistry
6. Carnegie Mellon neuroscientist develops tool to image brain function at the cellular level
7. Carnegie Mellon U. imaging study reveals sex-based differences that persist as mice enter adulthood
8. Carnegie Mellon computational biologist Russell Schwartz receives prestigious CAREER award
9. Carnegie Mellon U. develops microgel to recover enzymes for manufacturing, research assays
10. Carnegie Mellon U. conducts first comprehensive proteomic analysis of developing animal
11. Pittsburgh NMR Center for Biomedical Research at Carnegie Mellon

Post Your Comments:
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: